Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Huwel’s diagnostic solutions leverage open RT-PCR system
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The first of four planned modules at the new plant is expected to come online by summer 2026
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
Subscribe To Our Newsletter & Stay Updated
